6 results found.

Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II M Clinical Trial using carfilzomib; dexamethasone; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2).
carfilzomib; dexamethasone; laboratory biomarker analysis

Stage I Multiple Myeloma, Stage II Multiple Myeloma, or Stage III Clinical Trial using ixazomib; cyclophosphamide; dexamethasone; pharmacological study; questionnaire administration; quality-of-life assessment

Mayo Clinic - Recruiting 18 years or older.
- Phase 1/2 Trial of MLN9708 in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma.
ixazomib; cyclophosphamide; dexamethasone; pharmacological study; questionnaire administration; quality-of-life assessment

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Relapsed Multiple Myeloma, or End-stage Renal Disease Clinical Trial using Carfilzomib

Onyx Pharmaceuticals - Recruiting 18 years or older.
- An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease.
Carfilzomib

Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II M Clinical Trial using romiplostim

New York University School of Medicine - Recruiting 18 years or older.
- Phase II Trial Evaluating the Efficacy and Safety of Romiplostim (Nplate) Treatment of Chemotherapy Induced Thrombocytopenia in Patients With Multiple Myeloma.
romiplostim

Stage I Multiple Myeloma, Stage II Multiple Myeloma, or Stage III Clinical Trial using dexamethasone; carfilzomib; lenalidomide; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

University of Chicago - Recruiting 18 years or older.
- Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy.
dexamethasone; carfilzomib; lenalidomide; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis